Page 41 - Read Online

Kaya et al. Neuroimmunol Neuroinflammation 2019;6:5 I http://dx.doi.org/10.20517/2347-8659.2018.70 Page 15 of 15

75. Gastwirt RF, Slavin DA, McAndrew CW, Donoghue DJ. Inhibition of apoptosis and checkpoint activation. J Biol Chem
2006;281:35425-35.
76. Dhariwala FA, Rajadhyaksha MS. An unusual member of the cdk family: cdk5. Cell Mol Neurobiol 2008;28:351-69.
77. Yip YP, Capriotti C, Drill E, Tsai LH, Yip JW. Cdk5 selectively affects the migration of different populations of neurons in the
developing spinal cord. J Comp Neurol 2007;503:297-307.
78. Fu X, Choi YK, Qu D, Yu Y, Cheung NS, et al. Identification of nuclear import mechanisms for the neuronal Cdk5 activator. J Biol
Chem 2006;281:39014-21.
79. Cruz JC, Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer’s disease. Trends Mol Med 2004;10:452-8.
80. Zhang J, Krishnamurthy PV, Johnson GVW. Cdk5 phosphorylates p53 and regulates its activity. J Neurochem 2002;81:307-13.
81. Sedarous M, Keramaris E, O’Hare M, Melloni E, Slack RS, et al. Calpains mediate p53 activation and neuronal death evoked by DNA
damage. J Biol Chem 2003;278:26031-8.
82. Wu GS. The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol Ther 2004;3:156-61.
83. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53regulated genes. Nat Rev Mol Cell Biol 2008;9:402-12.
84. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009;9:724-37.
85. McCubrey JA, Linda S, Terrian DM, Milella M, Tafuri A, et al. Roles of the RAF/MEK/ERK pathway in cell growth, malignant
transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84.
86. Sawe N, Steinberg G, Zhao H. Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. J Neu rosci Res 2008;86:1659-69.
87. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol_induced activation of p53 and apoptosis is mediated by extracellular_
signal_regulated protein kinases and p38 kinase. Cancer Res 2001;61:1604-10.
88. Duan WJ, Li QS, Xia MY, Tashiro S, Onodera S, et al. Silibinin activated p53 and induced autophagic death in human fibrosarcoma
HT1080 cells via reactive oxygen species p38 and C-Jun N-terminal kinase pathways. Biol Pharm Bull 2011;34:47-53.
89. Xiao Y, Yan W, Lu L, Wang Y, Lu W, et al. p38/p53/miR-200a-3p feedback loop promotes oxidative stress-mediated liver cell death.
Cell Cycle 2015;14:1548-58.
90. Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin.
J Biol Chem 2000;275: 35778-85.
91. Kaji A, Zhang Y, Nomura M, Bode AM, Ma WY, et al. Pifithrin-alpha promotes p53- mediated apoptosis in JB6 cells. Mol Carcinog
2003;37:138-48.
92. Lin T, Mak NK, Yang MS. MAPK regulate p53 dependent cell death induced by benzo[a]pyrene: involvement of p53 phosphorylation
and acetylation. Toxicology 2008;247:145-53.
93. Drosten M, Sum EY, Lechuga CG, Simón Carrasco L, Jacob HK, et al. Loss of p53 induces cell proliferation via Ras-independent
activation of the Raf/Mek/Erk signaling pathway. Proc Nat Acad Sci U S A 2014;111:15155-60.
94. Singh S, Upadhyay AK, Ajay AK, Bhat MK. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a
novel target of p53 in apoptosis. FEBS Lett 2007;581:289-95.
95. Lee SY, Shin SJ, Kim HS. ERK1/2 activation mediated by the nutlin-3-induced mitochondrial translocation of p53. Int J Oncol
2013;42:1027-35.
96. Ongusaha PP, Kim JI, Fang L, Wong TW, Yancopoulos GD, et al. p53 induction and activation of DDR1 kinase counteract p53-
mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO J 2003;22:1289-301.
97. Bermudez O, Jouandin P, Rottier J, Bourcier C, Pagès G, et al. Post-transcriptional regulation of the DUSP6/MKP3 phosphatase by
MEK/ERK signaling and hypoxia. J Cell Physiol 2011;226:276-84.
98. Zhang H, Chi Y, Gao K, Zhang X, Yao J. p53 protein-mediated upregulation of MAP kinase phosphatase 3 (MKP3) contributes to the
establishment of the cellular senescent phenotype through dephosphorylation of extracellular signalregulated kinase 1/2 (ERK1/2). J
Biol Chem 2015;290:1129-40.
99. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKT action blocks apoptosis. Cell 1997;88: 435-7.
100. Wymann MP, Pirola L. Structure and function of phosphoinositide 3-kinases. Biochim Biophys Acta 1998;1436: 127-50.
101. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
102. Sabbatini P. McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally
dependent apoptosis. J Biol Chem 1999;274:24263-9.
103. Henry MK, Lynch JT, Eapen AK, Quelle FW. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation
of the PI-3 kinase/Akt signaling pathway. Blood 2001;98:834-41.
104. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide
3-kinase/AKT pathway. Proc Natl Acad Sci 1999;96:4240-5.
105. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, et al. Regulation of G1 progression by the PTEN tumor suppressor protein
is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci 1999;96:2110-5.
106. Rossignol S, Schwab M, Schwartz M, Fehlings MG. Spinal cord injury: time to move? J Neurosci 2007;27:11782-92.
107. Van den Berg ME, Castellote JM, Mahillo-Fernandez I, dePedro- Cuesta J. Incidence of spinal cord injury worldwide: a systematic
review. Neuroepidemiology 2010;34:184-92.